DelveInsight’s Hyperphosphatemia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Hyperphosphatemia Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Hyperphosphatemia market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Hyperphosphatemia: Overview
Hyperphosphatemia is a condition that is characterized by an increased level of phosphate in the blood. It is asymptomatic effect/condition of another major underlying cause. The normal range for phosphorous is 2.5-4.5 mg/dL. Normal values may vary from laboratory to laboratory.
Get access to a free copy of our latest sample report @ https://www.delveinsight.com/sample-request/hyperphosphatemia-market
Some of the key facts of the Hyperphosphatmia Market
- As per the Centers for Disease Control and Prevention (2021), more than 1 in 7, i.e., 15% of US adults are estimated to have CKD and as many as 9 in 10 adults with CKD do not know they have CKD. CDC also mentioned that 2 in 5 adults with severe CKD do not know they have CKD.
- More than 661,000 Americans have kidney failure. Of these, 468,000 individuals are on dialysis, and roughly 193,000 live with a functioning kidney transplant (National Institute of Diabetes and Digestive and Kidney Diseases, n.d).
- As CKD progresses, modest increases in serum phosphate levels within the normal range increase the filtered load of phosphate, and at the same time, the fractional excretion of filtered phosphate increases from 10% to >50%. Only after these compensations are exhausted does overt hyperphosphatemia occur, typically in CKD stages 4-5.
Hyperphosphatemia market size is anticipated to increase during the study period owing to the increasing incident population and rising awareness of Hyperphosphatemia in the 7MM. The expected launch of emerging therapies and the research and development activities of pharmaceutical companies will also fuel the market growth during the forecast period.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Hyperphosphatmia market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Hyperphosphatmia market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Hyperphosphatemia Market Insights
Excess phosphorus levels in ESRD have been linked to a rise in the risk of cardiovascular disease, as well as rises in serum Fibroblast growth factor 23 (FGF-23), a significant serum endocrine hormone that controls phosphorus metabolism, and elevated parathyroid hormone, also known as secondary hyperparathyroidism. Since dialysis is not efficient at removing excess phosphorus, the mainstay of treatment in patients with hyperphosphatemia in advanced chronic kidney disease is the reduction of phosphate intake, which is usually accomplished with avoidance of foods containing high amounts of phosphate and with the use of phosphate-binding drugs taken with meals. Although quite effective, aluminum-containing antacids should not be used as phosphate-binding agents in patients with end-stage renal disease because of the possibility of aluminum-related dementia and osteomalacia (a condition where bones become soft and weak).
Hyperphosphatmia Treatment Market
In September 2014, Auryxia (ferric citrate) was approved by the US FDA for the control of serum phosphorus levels in adults with CKD on dialysis. Apart from this, branded and generic version Sevelamer is available in the market, to control phosphorus levels in adults and children. Fosrenol is a phosphate binder that is indicated for use in ESRD (stage 5) receiving dialysis and, from October 2009, is also indicated in the EU for the treatment of adult patients with CKD who are not on dialysis with serum phosphate > 1.78 mmol/L (5.5 mg/dL) in which a low phosphate diet alone is insufficient to control serum phosphate levels.
Hyperphosphatmia Epidemiology
The epidemiology section covers insights about the historical and current Hyperphosphatmia patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Hyperphosphatmia Drugs & Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hyperphosphatmia market or expected to get launched in the market during the study period. The analysis covers Hyperphosphatmia market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Hyperphosphatmia Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Hyperphosphatmia Therapeutics Analysis
Companies all over the globe are persistently working toward the development of new treatment therapies for Hyperphosphatmia. The launch of the emerging therapies is expected to transform the treatment dynamics in the coming years.
Hyperphosphatmia Market Dynamics
The dynamics of the Hyperphosphatemia market is anticipated to change as companies across the globe are thoroughly working toward the development of new drug therapy options to treat this indication. Key players, such as Ardelyx/Kyowa Hakko Kirin, Shield Therapeutics, Chugai Pharmaceutical, Daiichi Sankyo and others are involved in developing novel therapies for Hyperphosphathemia which will eventually influence the market size during the forecast period [2021–2030].
Hyperphosphatmia Companies includes-
- Akebia Therapeutics
- Vifor Fresenius Medical Care Renal Pharma
- Astellas Pharma
- Ardelyx
- Shield Therapeutics, and others
Hyperphosphatmia Therapies includes-
- Auryxia (ferric citrate)
- Tenapanor
- PT-20, and others
View Detailed Report of key players and therapies @ https://www.delveinsight.com/sample-request/hyperphosphatemia-market
Hyperphosphatmia Market Drivers
- Expected rise in cases of chronic kidney disease and patients progressing towards end stage renal disease
- Emerging assets targeting underlying cause of Hyperphosphatemia with strong safety profile and reducing pill burden
Hyperphosphatmia Market Barriers
- Frequent dosing pattern of phosphate binders
- Safety and tolerability concerns of approved therapies
Table of content
- Key Insights
- Executive Summary
- Competitive Intelligence Analysis
- Market Overview at a Glance
- Disease Background and Overview
- Patient Journey
- Epidemiology and Patient Population
- Treatment Algorithm, Current Treatment, and Medical Practices
- Unmet Needs
- Key Endpoints of Hyperphosphatmia Treatment
- Marketed Products
- Emerging Therapies
- Seven Major Market Analysis
- Attribute analysis
- 7MM: Market Outlook
- Access and Reimbursement Overview
- KOL Views
- Market Drivers
- Market Barriers
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/